These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Compensated cardiogenic shock: a subset with damage limited to liver and kidneys. The possible salutary effect of low-dose dopamine. Naschitz JE; Yeshurun D Cardiology; 1987; 74(3):212-8. PubMed ID: 3594510 [TBL] [Abstract][Full Text] [Related]
3. Predictors of hepatorenal syndrome in alcoholic liver cirrhosis. Janicko M; Veseliny E; Senajova G; Jarcuska P Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):661-5. PubMed ID: 25820623 [TBL] [Abstract][Full Text] [Related]
4. [Acute heart failure: acute cardiogenic pulmonary edema and cardiogenic shock]. Sánchez Marteles M; Urrutia A Med Clin (Barc); 2014 Mar; 142 Suppl 1():14-9. PubMed ID: 24930078 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic approaches to the treatment of edema and ascites: the use of diuretics. Somberg JC; Molnar J Am J Ther; 2009; 16(1):98-101. PubMed ID: 19142158 [TBL] [Abstract][Full Text] [Related]
7. The management of hepatorenal syndrome. Carl DE; Sanyal A Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378 [TBL] [Abstract][Full Text] [Related]
8. [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin]. Gülberg V; Luppa P; Pauletzki J; Paumgartner G; Gerbes AL Z Gastroenterol; 1998 Dec; 36(12):1053-8. PubMed ID: 10025057 [TBL] [Abstract][Full Text] [Related]
9. Hepatorenal syndrome: pathogenesis and novel pharmacological targets. Barada K Curr Opin Pharmacol; 2004 Apr; 4(2):189-97. PubMed ID: 15063365 [TBL] [Abstract][Full Text] [Related]
10. Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. Eisenman A; Armali Z; Enat R; Bankir L; Baruch Y J Intern Med; 1999 Aug; 246(2):183-90. PubMed ID: 10447787 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of severe hepatorenal syndrome with living donor liver transplantation. Demirbas BT; Piskin T; Dayangac M; Yaprak O; Oklu L; Yuzer Y; Tokat Y Hepatogastroenterology; 2012 Oct; 59(119):2305-6. PubMed ID: 23435146 [TBL] [Abstract][Full Text] [Related]
13. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397 [TBL] [Abstract][Full Text] [Related]
14. [Vasoconstrictors in the treatment of hepatorenal syndrome]. Ortega R; Calahorra B; Ginès P Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919 [No Abstract] [Full Text] [Related]
15. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation]. De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199 [TBL] [Abstract][Full Text] [Related]